NICE statement on neuropathic pain guidelines
22nd July 2010
The UK National Institute for Health and Clinical Excellence (NICE) has posted a statement on it's website with reference to the concerns on the recommendation of the use of pregabalin (taken directly from source):
"NICE is aware that there have been concerns about the associated costs that pregabalin may bring to the NHS as one of the first line treatment options for adults with neuropathic pain. NICE, in collaboration with the Health Technology Assessment group are reviewing the economic modeling. Until a further announcement is made, the guideline continues to represent best practice for the NHS."
Recent news
- SMC accepts fentanyl single dose nasal spray
- NICE end of life care commissioning guide
- AWMSG approve tapentadol m/r for restricted use
- US FDA approve fentanyl sublingual spray
- NPSA Rapid Response Report on spinal connectors
- Update: anti-epileptics monograph
- NPC review m/r oxycodone/naloxone
- Prednisolone EC blister packs recalled from Teva
- Citalopram and escitalopram maximum daily doses restricted
- Extemporaneous thalidomide oral suspension stability study
News archive
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000